Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 2INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Breast 2Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 11Prostatic Neoplasms 7Neoplasm Metastasis 5Ovarian Neoplasms 4Neoplasms 4Triple Negative Breast Neoplasms 3Endometrial Neoplasms 3Small Cell Lung Carcinoma 2Fallopian Tube Neoplasms 2mCRPC 1Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Pheochromocytoma 1Pathologic Complete Response 1Paraganglioma 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 105Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 47Nivolumab 40Paclitaxel 35Gemcitabine 30Radiosurgery 29Carboplatin 28Irinotecan 22Ipilimumab 22Cyclophosphamide 22Cisplatin 22trastuzumab deruxtecan 21Leucovorin 19Capecitabine 19Fluorouracil 18Cetuximab 18Bevacizumab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fulvestrant 17Drug Therapy 16Docetaxel 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14palbociclib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neoplasm Metastasis × talazoparib × 1 year × Clear all
NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

National Cancer Institute (NCI)

Phase 2 Recruiting
36 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT05327010 2026-05-13

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
88 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04693468 2026-03-13

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

M.D. Anderson Cancer Center

Phase 1 Recruiting
111 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04991480 2026-01-27

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Artios Pharma Ltd

Phase 1 Completed
93 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02286687 2026-01-02

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
150 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡